

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee		In accordance with letter dated	4. Expiration Date: December 31, 2021
1. Ashford Presbyterian Community Hospital Nuclear Medicine and Cardiovascular Laboratory		March 28, 2017	5. Docket No.: 030-09858 Reference No.:
2. P.O. Box 9020032 San Juan, PR 00902-0032		3. License number: 52-11810-02 is amended in its entirety to read as follows:	
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1.1 curies total	C. For any use permitted by 10 CFR 35.300.

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located on the 1st, 2nd, and 3rd Floors, 1451 Ashford Avenue, San Juan, Puerto Rico.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
52-11810-02Docket or Reference Number
030-09858

Amendment No. 17

11. The Radiation Safety Officer (RSO) for this license is David Rhoe.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized Users</u> | <u>Material and Use</u> |
|---------------------------------|---|
| Carlos E. Jiménez, M.D. | 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 |
| Bartolo Santiago-Delgado, M.D. | 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 |
| Roberto A. Annexy-Márquez, M.D. | 10 CFR 35.100, 10 CFR 35.200; Oral administration of sodium iodide Iodine-131 |
13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
52-11810-02Docket or Reference Number
030-09858

Amendment No. 17

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated June 29, 2011 [ML11870423]
- B. Letter dated December 19, 2011 [ML113550118]
- C. Letter dated December 22, 2014 [ML15012A408]
- D. Letter dated December 1, 2015 [ML15350A164]
- E. Facility diagram dated January 14, 2016 [ML16027A050]



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: April 26, 2017

By: _____

Penny Lanzisera
Penny Lanzisera
Region 1